kurzfristige Spekulationen: MediGene


Seite 11 von 15
Neuester Beitrag: 05.02.19 12:22
Eröffnet am:27.11.10 19:56von: Mr. Sam.Anzahl Beiträge:368
Neuester Beitrag:05.02.19 12:22von: gripsLeser gesamt:123.058
Forum:Börse Leser heute:9
Bewertet mit:
5


 
Seite: < 1 | ... | 8 | 9 | 10 |
| 12 | 13 | 14 | ... 15  >  

94 Postings, 4669 Tage Aktien TraderWe will rock MDG...

 
  
    #251
12.02.12 21:43

http://www.pharma-mag.com/

Liebe Leser,

Morgen wird sich zeigen, ob die Konsolidierung abgeschlossen ist. Die Nachhaltigkeit hat sich seitdem 02.01.2012 gehalten.

Vor uns steht noch das 2. Halbzeit im 1. Q, d. h.

1. 5. Mio. aufs MDGs Konto;

2. Veregens Einführung in Spanien;

3. Positive Entscheidung, dass Veregen in 17 Läbder anerkannt wird;

4. 13.-14.02.2012 BIO CEO & Investor Conference in NY, USA;

5. 19.-21. 3.2012 BIO-Europe Spring in Amsterdam;

6. 23.03 Veröffentlichung des Geschäftsberichts 2011.

Das war die öffentliche Liste was auf MDG zukommt und das war nicht alles. Die geheime Liste kennen nur die guten 2.

Wir lassen uns gerne überraschen! aber in Kürze noch!

 

 

Viel Glück.

 

 

94 Postings, 4669 Tage Aktien TraderGrüner Tag: Interview mit Yoshihiko Hatanaka

 
  
    #252
1
13.02.12 18:22

Lieber Leser,

hier ist ein

Interview: Yoshihiko Hatanaka, CEO and president, Astellas

When Yoshihiko Hatanaka was appointed president and CEO of Astellas Pharma last June, the six-year-old company was already moving in a direction he had played a large role in setting. He was part of the merger preparation committee that oversaw the fruitful union of two of Japan’s oldest pharmaceutical companies, Fujisawa and Yamanouchi, in 2005.

The following year, he was instrumental in starting VISION 2015, the company’s roadmap to 2015. Then, in 2010, he took the lead in developing the mid-term plan through to 2014. “So, although the leadership changed last June, I won’t be changing the direction of the current Astellas,” he says.

That means continuing to work towards global category leadership in areas with high unmet needs under the corporate ethos entitled ‘Changing Tomorrow’. In Astellas’ case, that means building on the strong positions it has already established in urology and transplantation and continuing to develop its presence in oncology.

Future areas for global category leadership include immunology and infectious disease, neuroscience, diabetes mellitus (DM) complications and metabolic diseases. Such a strategy, when coupled with stripping the business of anything not in the innovative pharmaceutical space – generics, over-the-counter products and diagnostics – puts the mid-sized company firmly at the high end of the medicines business. 

“When we were developing our long-term vision, we expected market conditions – such as governments striving to manage increasing healthcare costs, heavy generic competition and higher regulatory hurdles – to persist,” he explains. “So we discussed how we could become a sustainable organisation under such conditions.”

 

The pure pharma player is a natural response to what many see as the hollowing out of the medicines business over the next few years, with generics companies at one end of the spectrum and innovative ones at the other, with very little in between. But aspiring to be a global category leader requires something extra. Hatanaka describes this as a combination of world-class knowledge and utilising close relationships with regulatory bodies and contacts with key external experts.

Precision medicine
“To take a leadership position, obviously innovation is key,” he says. “So, how can we increase our R&D productivity while also managing costs? These are questions every pharmaceutical company is asking. Our approach, as far as R&D is concerned, lies in precision medicine. In the past, a mass medicine approach worked well, but now we have to carefully categorise our position and identify sub-populations of patients that will benefit from our products in terms of better efficacy or less side effects.”

Astellas knows the old approach well, having licensed Lipitor from Pfizer in the Japanese market. According to the business intelligence database, EvaluatePharma, the company earned $1.37bn in 2010 from what was the world’s best-selling drug, but these revenues are expected to halve by 2016, now it is off patent, to $667m.

The choice of cancer as the third area for global category leadership was determined by the high level of unmet need in this area, but it is also a natural fit for a precision medicine approach. Indeed, the company’s first step towards developing a presence in oncology was its acquisition, in December 2007, of Agensys, a private US biotech firm that focuses on antibody technology. Three years later, the company acquired OSI Pharmaceuticals for $4bn, which brought with it not only a blockbuster drug in Tarceva and an experienced oncology sales force, but also, given its specialisation in small molecule discovery, research capabilities that complement those of Agensys.

The company also has various in-licensing deals in the oncology space, including one concluded last year worth $1.4bn with Aveo Pharmaceuticals for tivozanib, which is currently being tested in renal cell cancer among other indications. It acquired the European marketing rights to Eligard, a prostate cancer drug, from MediGene via this route and is co-developing a compound for acute myeloid leukaemia with Ambit.

Astellas now has 15 clinical development projects in oncology, the most advanced of which is MDV3100, a first-in-class androgen-receptor signalling inhibitor that recently produced positive phase III results from an interim analysis in men with advanced prostate cancer previously treated with chemotherapy.

R&D resources
Having sufficient resources to be a pure pharma player was one of the criteria for the merger of Yamanouchi and Fujisawa. “Our first objective was to be able to spend more than $1bn a year on R&D,” says Mr Hatanaka. “That was considered key to play within the pharmaceutical market.” According to EvaluatePharma, Astellas’s R&D spending stood at $2.5bn in 2010, around 20 per cent of its revenues.

The second objective was to expand the company’s reach across the globe. Both constituent parts were headquartered in Japan and had some presence in the Asian territories, but Yamanouchi was strong in Europe and Fujisawa in the US. Now, while 50 per cent of the sales of Japan’s second-largest pharma company still come from the domestic market, Europe and the US roughly share more than 40 per cent, with the rest of the world accounting for around five per cent. The third objective was to increase the talent pool. “Now, when I look back on these three objectives, I am happy because I believe we have achieved them all,” he says.

This ultra-clear management style filters through all the company’s operations. VISION 2015 highlighted three systems that would help fulfil its goal of global category leadership. One involves its more than 16,000-strong workforce within its ‘human resources management system’.  “We realise that innovation comes from people, so talent is the most important thing for us to drive our business,” he says. To that end, he continues, it is “an important strategic objective” to be an employer of choice, something he claims has now been recognised in the US, Japan, Korea and several European countries where it has a presence.

But being a preferred place to work does not guarantee the talent required to be a global leader. So, in October 2011, Astellas launched the first cohort of a training programme – the Executive Leadership Series – to create top-tier personnel in Europe, US and Asia with the appropriate skill sets. In particular, Hatanaka states that that means thinking with a global mindset.

Having worked in the US and Europe for Fujisawa and headed the Astellas US operation from 2006 to 2009, he knows something about the profound cultural differences that can so easily hamper global business negotiations. As such, he tries to encourage his management team not to think of Tokyo as the centre of its universe, but to take a more detached, loftier perspective. “I want people to think cosmically,” he says. “I try to imagine that I am stationed in space looking down on the earth with no cultural divisions.”

The second facility within VISION 2015 to help realise global category leadership is a ‘management control system’ to enable quicker and better decision-making. This places strong emphasis on communicating the company’s direction and ethos right down to employee level. Indeed, Mr Hatanaka describes this Japanese management approach as one of three aspects that makes Astellas unique within the pharma business, the others being its business model as a pure pharma player and its pursuit of leadership in clear therapeutic areas.

 

Information sharing
“We try to share as much information as possible with our employees,” he says. “It is very important to get commitment from each of them and to share the same kind of direction and vision.” Underpinning that direction are the core values of Astellas, the primary one of which is that patient health always comes first. “Wherever I go and any opportunity I have, I stress that every job is related to patient health,” he continues. “This is a message not only for our medical representatives, the researchers or those in development work. Nor is it just for our external stakeholders. All supporting jobs at Astellas are also focused on patient health. Another important thing I want to mention is that we share this common value while at the same time respecting diversity. This is our philosophy and a good way of expressing how Astellas operates,” he adds.

It is a message that will have featured strongly during Mr Hatanaka’s recent trip to London when a number of so-called ‘town hall’ meetings with employees were scheduled, as well as a dinner with the managing directors of the major European affiliates. “Although we have several ways of communicating strategy globally, still face-to-face meetings are best,” he asserts.

The third system to realise global category leadership, Mr Hatanaka explains, is management based on corporate social responsibility (CSR) with integrity and compliance at its core. “To be a sustainable business, it is important to gain the trust or credibility of the community or our customers,” he goes on. “This is because it can take more than a decade to build up, but can be lost in a second.”

One way of building that trust is to offer company employees the opportunity to undertake voluntary projects that benefit their local community. In the seven months to October 2011, some 6,000 staff across the world had taken part in such projects that included teaching healthy eating to children, gardening, building and painting fences, and cleaning up areas of the community.

Such local endeavours make more sense when seen through the philosophy underpinning CSR-based management. The company describes this as ‘a programme through which we strive towards sustained enhancement of enterprise value while remaining acutely aware of our social responsibilities and taking a broad view that considers economics, society and humanity, so that we can exist not just as a market entity but also a meaningful member of society’.

Mr Hatanaka’s commitment to that noble goal is arguably best summed up in his clarity of vision regarding the company’s focus on innovation, on patients and on direct communication to the workforce, so everyone can speak with one voice.

http://www.pmlive.com/pharma_news/...hihiko_hatanaka,_astellas_361696

 

Viel Glück

 

42 Postings, 7106 Tage guego01zu 250 von Aktien Trader

 
  
    #253
13.02.12 18:34
woraus schließt du, dass endotag immer beliebter wird? weißt du mehr oder ist das nur kaffeesudlesen? ich seh derzeit keinen zusammenhang von endotag mit den kursanstiegen der letzten tage!  

94 Postings, 4669 Tage Aktien TraderMedigene zwischen 15.02. bis 23.03.2012...

 
  
    #254
1
14.02.12 20:00

Leber Leser,

es ist bemerkenswert, dass die Bio Pharma Industrie, seit Anfang des Jahres 2012, die Börse dominiert. Und immer in Top 50 zu finden, und immer am spekulativesten. Bei MDG wird rechtzeitig zugeschlagen und ich denke es ist nicht zu weit, denn die o. g. Zeitangabe ist berechtigt. Sollte das Management nicht mitspielt, dann darf MDG bis Ende 2013 noch kein EndoTag-Partner finden. Es ist hart zu behaupten, aber wahr!

Ich bin zuversichtlich, dass alles gut wird, MDG selbst wird es bestätigen können... in Kürze

Bleibt wie immer ABWARTEN.

 

Viel Glück

 

317 Postings, 4866 Tage TiKalistAuf Regen folgt Sonnenschein bis zum 04.05.2012

 
  
    #255
1
14.02.12 21:51

selbst wenn irgendetwas in Richtung Verpartnerung passiert bis zum 25.03, dann nicht weil es hier in diesem Thread geschrieben wurde.

 

Ich sage Voraus das auf tiefe Kurse hohe Folgen werden. Mediginelein ist auf nem guten Weg.

Ich sehen in der Kugel das die Plattform verkauft wird....nicht verpartnert!

 

Bushfire burning!

 

94 Postings, 4669 Tage Aktien Trader2. Anlauf steht vor uns...

 
  
    #256
1
20.02.12 19:34

Liebe Leser,

vor kürzem habe ich meine Einschätzungen nicht konkretisiert. Aber wenn die NEWS nicht kommen, dann machen wir welche bzw. "Positiv Denken", nicht mit "Proof of Concept", sondern mit "Wenn, Dann Prinzip".....Es ist Bio Pharma Industrie. Also bis 30.03.2012 soll MDG:

1. 5. Mio. bekommen; Wenn, dann 10-25 Cents Anstieg...

2. Die Markt-Einführung von Veregen in Spanien bekannt geben; Wenn, dann 7-15 Cents Anstieg...

3. Eine Positive Entscheidung, Veregen in 17 Länder Europas; Wenn, dann 7-10 Cents Anstieg

4. 23.03 Veröffentlichung des Geschäftsberichts 2011, zum ersten mal Schwarze Zahlen.

Mit die 4 Punkte gelengen wir auf 1,50 bis 1,60 €, nach roten Tagen und viel Optimismus.

Sonder Bemühungen und NEWS werden nicht mitgerechnet, aber Wenn, dann Explosion zwischen 1,75 und 2,50 an einem Tag möglich. Die Vergangenheit zeigt keine Optimismus, aber RhuDex-Partnerschaft bis Mitte des Jahres nach "EULAR Annual European Congress of Rheumatology" ist möglich und damit 100 % ab jetzt machbarer als 700 % mit EndoTag.

Wir freuen uns auf das Management.

 

Viel Glück bei der Umsetzung

 

Viel Glück.

 

94 Postings, 4669 Tage Aktien TraderEndoTag in Vivo

 
  
    #257
1
21.02.12 19:03
ENDOTAG-1®, A CATIONIC LIPOSOMECONTAINING PACLITAXEL, DEMONSTRATES ANTI-ANGIOGENIC AND ANTI-INFLAMMATORY ACTIVITY IN RHEUMATOID ARTHRITIS IN VIVO

Abstract

Introduction: Inflammation and angiogenesis are hallmarks of rheumatoid arthritis (RA) that contribute largely to the formation of pannus tissue and joint destruction in patients suffering from RA. We have recently shown that intravenously applied cationic liposomes target efficiently angiogenic endothelial cells in the synovial vasculature of rheumatoid joints and therefore may also serve as potent vehicles for systemic drug delivery and therapy in RA. Therefore the aim of our study was to quantify the antiangiogenic and antiinflammatory properties of EndoTAG-1® (paclitaxel formulated in cationic liposomes) in the inflamed joints of murine models of RA and to compare the therapeutical efficacy of EndoTAG-1® to Taxol® (paclitaxel in Cremophor EL).

Materials and Methods: Targeting of fluorescently labelled cationic liposomes to the synovial vasculature in mice with antigen-induced arthritis (AIA) was analysed by intravital microscopy. Density of functional vessels and adhesion of fluorescently labelled platelets or leukocytes were determined after treatment with EndoTAG-1®. Knees were subjected to clinical scoring and histopathological analysis.

Results: EndoTAG-1® treatment of AIA mice with developing or in established disease showed a strong attenuation of the course of the disease as well as a potent anti-inflammatory effect. Histological analysis of knee sections demonstrated a dramatic reduction of the pannus and infiltration of inflammatory cells. Enrichment of EndoTAG at the synovial vasculature of AIA mice was observed when compared with healthy mice. Treatment of AIA mice with EndoTAG-1® concomitant to disease induction showed a complete remission of the course of the disease as shown by a significant decrease of clinical scores compared to both control and Taxol® treated groups. A complete inhibition (98%) of neo-vascularisation was observed in the synovial vasculature of mice with AIA that were treated with EndoTAG-1® whereas Taxol® alone showed only 50% inhibitory effect. Rolling and adhesion of platelets were reduced to 53% (paclitaxel 5%) and 98% (paclitaxel 57%), respectively.

Discussion: Our in vivo data clearly demonstrates that anti-angiogenic and anti-inflammatory activity of Endo-TAG-1® contribute to the therapeutical efficacy of this drug in RA. Notably, therapeutic efficacy with Endo-TAG-1® was superior to Taxol®. This strongly suggests that systemic delivery of cationic liposomes is very well suited to enrich compounds to rheumatoid joints for therapy and could be a promising treatment option for RA.

Footnotes

  • Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org

http://proceedings.jbjs.org.uk/content/92-B/SUPP_II/280.1.short

 

94 Postings, 4669 Tage Aktien TraderTrotzdem bleibt ein Partner aus......

 
  
    #258
1
21.02.12 19:10

EndoTAG1

In EndoTAG®-1 the active component is hydrophobic. The drug is inserted into the lipid bilayer, and in particular its hydrophobic compartment (Fig. 4), which acts as a two-dimensional solvent for the compound. EndoTAG®-1 comprises the diterpenoid paclitaxel (44), a potent antimitotic agent widely used in cancer therapy (45). Paclitaxel has a very low solubility in water (in the order of 1 mg/L) and therefore its solubility must be increased for IV application. In Taxol® (Brystol-Myers Squibb), which is approved for treatment of advanced ovarian, breast, and non-small cell lung cancer in the United States and in Europe, paclitaxel is solubilized by a mixture of Cremophor® EL (BASF) and ethanol. However, Cremophor causes serious side effects such as hypersensitivity reactions and peripheral neuropathy (46,47). Prophylactic steroids and histamine receptor antagonists have to be coadministered with Taxol to reduce these effects. In addition, the maximum dose of paclitaxel is limited by neutropenia and neurotoxicity.

Great efforts to develop alternative formulations for paclitaxel are ongoing (48-50). Common goals are to provide sufficient solubility in aqueous environment, to improve pharmacokinetic and pharmacodynamic parameters, to reduce side effects and, possibly, to improve delivery to the target tissue of the drug.

Even though EndoTAG®-1 has another target than conventional paclitaxel-based products for cancer therapy, it can also be regarded as a lipo-somal approach for paclitaxel formulation (50). A significant number of studies on the liposomal formulation of paclitaxel has been published, and fundamental aspects of paclitaxel-membrane interactions have been investigated to detail by various methods (51-54). For development of EndoTAG®-1, an excessive screening of drug/lipid mixtures and formulation techniques has been carried out. Physicochemical characterization of drug-loaded model membranes was performed in order to get insight into general aspects of paclitaxel insertion into (cationic) lipid membranes. Inter alia, differential scanning calorimetry measurements, spectroscopic techniques, X-ray scattering, and Langmuir monolayer measurements (55,56) have been applied as tools to study paclitaxel membrane interactions and to define the formulation parameters.

Figure 6 shows the understanding of the molecular organization of paclitaxel in liposomal preparations which can be derived from such experiments (50). In addition to the paclitaxel, which is inserted into the liposomes,

Liposome Formulation Paclitaxel

Liposomal preparation of paclitaxel

Figure 6 Options for the partition of paclitaxel in liposome preparations. The drug is supposed to be inserted in the liposomal lipid bilayer. In addition, a fraction that is dissolved in water has to be taken into account. If the maximum solubility of pacli-taxel is exceeded, formation of microcrystals as a colloidal dispersion or a precipitate can occur.

Liposomal preparation of paclitaxel

Figure 6 Options for the partition of paclitaxel in liposome preparations. The drug is supposed to be inserted in the liposomal lipid bilayer. In addition, a fraction that is dissolved in water has to be taken into account. If the maximum solubility of pacli-taxel is exceeded, formation of microcrystals as a colloidal dispersion or a precipitate can occur.

it may be present in the aqueous phase, or as precipitated or colloidally dispersed crystallites. In equilibrium, there is a constant ratio between the concentration of paclitaxel in the liposome and in the aqueous phase (53). If liposomes are loaded with an amount of paclitaxel, which is higher than the equilibrium value, paclitaxel release and subsequent crystallization of the drug may have to be taken into account. In a practical pharmaceutical preparation, the concentration of paclitaxel should be about two to three orders of magnitude higher than its maximum solubility in water.

EndoTAG®-1, which is currently tested in clinical studies, comprises about 3 mol% paclitaxel in a DOTAP/DOPC lipid matrix. For application to a patient it is present as a colloidal dispersion of particles of uniform size of about 200 nm, where the total lipid concentration is 10 mM. For storage, the formulations are lyophilized, and they are reconstituted with water for injection directly prior use. A robust industrial scale process for manufacturing and lyophilization of liposomal products was developed (57), and is summarized in Figure 7. Lipids and paclitaxel are dissolved in ethanol at the appropriate molar ratio, and this concentrated solution is injected into the aqueous phase under stirring. Thus, drug-loaded, polydisperse liposomes are formed spontaneously by a self-assembly process. The size distribution of the liposomes is adjusted by several consecutive extrusion cycles through membranes of defined pore size. After sterile filtration, the preparation is filled into moulded vials and freeze-dried. By lyophilization of the product, a shelf life of more than two years is provided. Regular cGMP production has been performed with a bulk size of about 70 L, resulting in a reproducible and consistent quality of the final product in more than 15 production batches.

In a broad preclinical program, the biological effects of EndoTAG®-1 were studied in comparison to different controls, including Taxol. EndoTAG®-1 showed superior antitumor activity in a variety of different species and

Figure 7 Production scheme of EndoTAG®-1. Multilamellar liposomes are formed by ethanol injection of the lipid and drug solution into the aqueous phase. By extrusion and sterile filtration, monolamellar, monodisperse, and sterile liposomes are formed. Subsequently, the preparation is freeze-dried for storage.

Figure 7 Production scheme of EndoTAG®-1. Multilamellar liposomes are formed by ethanol injection of the lipid and drug solution into the aqueous phase. By extrusion and sterile filtration, monolamellar, monodisperse, and sterile liposomes are formed. Subsequently, the preparation is freeze-dried for storage.

tumor models. It significantly inhibited tumor growth, delayed the onset of metastasis, inhibited infiltration of healthy tissue surrounding the tumor, and increased the survival of tumor-bearing animals (16,58,59). Importantly and indicative for a different mode of action, EndoTAG®-1 inhibited tumor growth also in Taxol-resistant animal tumor models, as for example, B16 melanoma and Sk-Mel 28 melanoma. EndoTAG®-1 demonstrated a strong antivascular effect on the preexisting tumor vasculature and affected several tumor microcirculatory parameters. It reduced the endothelial cell mitotic rate in the vicinity of the tumor (58), caused a dramatic lasting reduction of tumor perfusion (59) and tumor vessel damage (59,60). There is evidence that continuous EndoTAG®-1 treatment can lead to tumor vessel leakage and enhanced accessibility of the tumor tissue for low-molecular-weight substances (60,61). EndoTAG®-1 treatment of mice bearing an orthotopically grown human pancreatic carcinoma led to a total suppression of liver metastasis. Combination of EndoTAG®-1 with the conventional chemotherapeutic drugs cisplatin (60) and gemcitabine (62) further enhanced tumor growth inhibition.

EndoTAG®-1 has passed a phase I clinical program with more than 150 patients with advanced metastatic cancer for determination of the safety and tolerability, and for investigation of the pharmacokinetic parameters.

EndoTAG® -1 appears to be a safe drug with an overall response rate of 8% to 14%; a range which is typical for effective drugs in phase I cancer trials. A large phase II trial for EndoTAG®-1 in combination with gemcitabine in patients with advanced or metastatic adenocarcinoma of the pancreas has started in 2005.

EndoTAG®-2

Also EndoTAG®-2 is a preparation for tumor therapy, but the molecular target of the active compound and the mechanism of loading the drug to the liposome are essentially different to those in EndoTAG®-1. The active compound in EndoTAG®-2 is camptothecin (CPT), a quinoline-based alkaloid, which can be isolated from the Chinese tree Camptotheca acuminata. CPT is a topoisomerase inhibitor, i.e., binding to the topoisomerase I-DNA complex induces DNA breaks and cell death (64).

A fundamental molecular property of CPT is its pH-dependent equilibrium between the lactone and the carboxylate form (Fig. 8, left side). The lactone form is lipophilic, whereas the carboxylate, which predominates at physiological pH and above, is water-soluble. Both molecular forms are present as equilibrium and one form can be transformed into the other one, for example, by changing the pH. The carboxylate form is considered to be less active and responsible for severe side reactions such as neutropenia, thrombocytopenia, and hemorrhagic cystitis (63). Therefore, efforts in the development of CPT drugs concentrated on the stabilization of the lactone

Lactone

 

 

http://www.78steps.com/lymph-nodes/endotag1.html

 

94 Postings, 4669 Tage Aktien TraderGutes Zeichen muss man zur Kenntnis nehmen...

 
  
    #259
1
21.02.12 22:17

Lieber Leser,

es ist fast ein Monat ohne News, trotz die vielen Reisen.

Ich denke wir werden morgen was zu lesen bekommen. Die Stille ist sehr unheimlich und ich glaube an MDGs Management. Worum es morgen geht, kann ich nicht sagen, aber ich denke positiv, hauptsache NEWS. Sollten wir nichts bekommen, mussen wir halt warten, warten und noch mal warten.

Ob zwischen 6:30 und 8:30 was kommt, das werden wir morgen erfahren. Oder auch NICHT!

Viel Glück an alle.

 

27132 Postings, 6161 Tage brunnetaWeißt schon jemand mehr wegen mehr Zulassung?

 
  
    #260
22.02.12 06:57
Ich meine wie kommt es voran?

MediGene: Start von Zulassungsprozessen mit Veregen® in 17 weiteren europäischen Ländern

vom 12. Dezember 2011

317 Postings, 4866 Tage TiKalistFM

 
  
    #261
22.02.12 18:06

Es wird gemunkelt FM möchte wieder besser schlafen...mit Erfolgsträumen  

 

94 Postings, 4669 Tage Aktien TraderEndoTag ist fast jeden Tag in Gespräch...

 
  
    #262
22.02.12 21:04
null  

94 Postings, 4669 Tage Aktien TraderDeal, Deal, Deal wo bleibst du?!

 
  
    #264
24.02.12 11:08

15. DISCONTINUED OPERATIONS  

 

On October 1, 2009, we divested the  Eligard product line as part of the sale of all of the shares of our U.S.  subsidiary, QLT USA, to Tolmar for up to an aggregate $230.0 million plus cash  on hand of $118.3 million. Pursuant to the stock purchase agreement, we received  $20.0 million on closing and $10.0 million on October 1, 2010 and we are  entitiled to future consideration payable on a quarterly basis in amounts equal  to 80% of the royalties paid under the license agreements with Sanofi Synthelabo  Inc. for the commercial marketing of Eligard in the U.S. and Canada, and the  license agreement with MediGene Aktiengesellschaft which, effective March 1,  2011, has been assigned to Astellas Pharma Europe Ltd. for the commercial  marketing of Eligard in Europe. The estimated fair value of these expected  future quarterly payments is reflected as Contingent Consideration on our  Consolidated Balance Sheet. We are entitled to these payments until the earlier  of our receipt of $200.0 million or October 1, 2024. As of December 31, 2011, we  had received an aggregate $86.1 million of contingent consideration. We expect  to receive the remaining $113.9 million on a quarterly basis, over the next  three to four years. The contingent consideration payments are not generated  from a migration or continuation of activities and therefore are not direct cash  flows of the divested business. We have not had any continuing involvement with  this business following its sale.

 

We recognized a pre-tax gain of  $107.4 million related to this transaction. The assets sold included $31.7  million of income tax assets, $14.9 million of accounts receivable, $10.6  million of inventory, $1.3 million of fixed and other assets, and $23.1 million  of goodwill. Liabilities of $7.3 million were assumed by Tolmar. See Note 16 -  Financial Instruments and Concentration of Credit Risk for further information  on fair value of contingent consideration.

 

In accordance with the accounting  standard for discontinued operations, the results of operations related to QLT  USA have been excluded from continuing operations and reported as discontinued  operations for 2009.

 

 

 

Operating results of QLT USA  included in discontinued operations are summarized as follows:

 

 

 

   September 30, 

(In thousands of U.S.  dollars)

January 1, 2009  -
October 1, 2009

Net product revenue

$28,625

Royalties

32,148
  

 

 

 
  60,773
  

 

 

 

Operating income

29,174

Other gains

1,828

Gain on sale of discontinued  operations

107,363
  

 

 

 

Income for discontinued operations  before income taxes

138,365

Provision for income  taxes

(2,711)
  

 

 

 

Net income from discontinued  operations

$135,654
  

 

 

 



Read more: http://www.faqs.org/sec-filings/120223/..._10-K/R24.htm#ixzz1nIBwGLx9

 

67687 Postings, 6089 Tage starwarrior03wie lang soll dieser Kladeradatsch hier eigentlich

 
  
    #265
2
24.02.12 16:01
wieder gehen??

alles was hier kurstechnisch die letzten Wochen geschah war mM nix anderes als eine Neueinpreisung Rhudex..  ;o)

ihr immer mit eurem EndoTAG da... :o( Ist eh Rubrik Ü-Ei mittlerweile und absolut ausgepreist.. Da ohne sachlich dienliche Hinweise was zu verlautbaren is nix anderes wie Glaskugel lesen..

grenzt eher an Pusherei, statt an Informationsweitergabe mit Tiefensinn.. ;o)

was aktuell interssiert ist Veregen, zwecks weiteren Zulassung aktuell.. dann die Zahlen zu 2011, dann Q1 2012 und dann Rhudex... Wenn da halt EndoTAG reinrutscht oder eben viel später - ist eben nur ein Ü-Ei Status aktuell, mehr nicht.. Gedealt werden wollte schon vor 3 jahren - nur zu Erinnerung.. Irgendwann nervt die ständige Wünscherei danach.. Das liegt in anderen Händen, Rubrik CEO und Co.. Von daher - konzentriert Euch auf das Ist nicht den Schein manches Postings hier..

Mfg
s03

Aktionär seit ü 7 jahren und "stetiger" jährl. Zu-Käufer.. ;o)  

94 Postings, 4669 Tage Aktien TraderCome back ab Nächste Woche erwartet...

 
  
    #266
24.02.12 17:19

@ starwarrior03 und co.

Lieber Leser,

wir bedauern die langjährige Treue, die inzwischen 7 Jahre ohne Gewinne zu erzielen. Was EndoTag betrifft, sagen wir "Man darf die Hoffnung nie aufgeben", außerdem könnte noch was großes drin sein.

Z. B. vorläufiger Partnerschaftsvertrag bis "Proof of Concept" feststeht, od. bis der Patentstreit beigelegt ist, darf vorhanden sein (natürlich ohne Leistungen). Man darf als Firma nicht alles offen legen. Ebenso dürfen wir als Anleger die Hoffnung nie aufgeben.

MDG hat es nicht verpasst....und die Zeit wird es noch beweisen.

 

Viel Glück

 

1008 Postings, 5589 Tage Nero.Hallo Leute!!

 
  
    #267
24.02.12 17:41
Sollche Werte brauchen Geduld,Zeit,Nerven und zuletzt viel viel Glück damit man keine kalten Füsse bekommt und zu früh den Handtuch wirft.  

94 Postings, 4669 Tage Aktien TraderNero hat Recht, und Come back bestätigt...

 
  
    #268
1
24.02.12 17:50

Lieber Leser,

Nero du hast es auf dem Punkt gebracht...... manche beleidigte Anleger halten sich zurück, wenn es schlecht läuft, komisch ist es aber wenn man grün aussieht, da tauchen sie plötzlich auf mit Friede Freude Eierkuchen: das sind keine ehrliche Anleger!

Vielen Dank für deine hervorragende Meinung Nero.

 

 

Viel Glück

 

94 Postings, 4669 Tage Aktien TraderArthritis Drugs 1.4 Billion Promise for German...

 
  
    #269
25.02.12 14:19

Alle werden auf "Arthritis Drugs" scharf sein.

http://www.bloomberg.com/news/2011-05-25/...aker-hinges-on-study.html

 

Viel Glück MDG

 

94 Postings, 4669 Tage Aktien TraderPhase I Clinical Trials Update: 21.02. 2012

 
  
    #270
1
25.02.12 16:46

Company (Location) Product Description Indication Status (Date)#  AUTOIMMUNE Enlivex Therapeutics Ltd. (Jerusalem) ApoCell Autologous, patient-specific drug Autoimmune diseases Completed patient enrollment in the Phase I/II trial (1/24) MediGene AG (Martinsried, Germany) RhuDex A CD80 antagonist Autoimmune disorders such as rheumatoid arthritis Starting a clinical formulation study aimed at developing an optimized oral formulation of the active substance in RhuDex (1/26) Protalex Inc. (Summit, N

BioWorld Insight | Tuesday, February 21, 2012
 
 
 
 
Wir kommen bestimmt noch...
 
Ab Montag, 27.02.2012 kann den Aufmarsch nach 1,50 - 1,75 ohne NEWS beginnen.
 
 
Viel Glück

 

 

94 Postings, 4669 Tage Aktien TraderMedigene: Unterschätzter Biotech-Pionier...

 
  
    #271
26.02.12 13:11

Lieber Leser,

es kommt jetzt darauf an ob MDG sich in die Biotech-szene durchsetzen kann oder nicht. MediGene hat alle Voraussetzungen letztendlich erfüllt. 2012 fängt bei MediGene erst morgen, den 27.02.2012 an. Verstärkung der Pipeline kommt auch dazu. Außerdem ist die heftige Konsolidierung am Freitag, den 24.02.2012 mit Erfolg abgeschlossen.

Wir rechnen mit mindestens ??? % in kürze Zeit, dank die Erwartungen die noch zu 100% und bis 31.03.21012 erfüllt werden müssen. Wir sind zuversichtlich, dass MediGene es schafft, uns bald zu überraschen!

(Pipeline-Verstärkung, EndoTag)

 

Viel Glück

 

67687 Postings, 6089 Tage starwarrior03sollten nicht schon vor 2-3 Wochen 1,50 bei Dir

 
  
    #272
26.02.12 14:31
fallen?? haste Schulden oder wie, das de deine Aktien loswerden willst???

hey, sorry, aber ich kann hier absolut nix nachaltiges lesen..  Sondern nur bekannte Dinge..
Bei mir fängt am 27.02. jedenfalls die nächste Kalnederwoche an mitten in 2012.. Wußte gar nicht, das MDG andere zeitrechnung hat..

Du sprichst von Liebe Leser und "wir" usw..

Für mich ist das Pusherei hier, und das braucht die Aktie absolut nicht...  hoffentlich fällt die Aktie, damit hier Ruhe einkehrt und sich wieder ums normale geschäft gekümmert wird..

Alles was Du größtenteils schreibst ist eigenes Wunschdenken und Bekanntes... Als Aktionär husch ich da nur drüber und schüttel den Kopf.. Weil mir bewußt is, das Du auch noch in 2-3 Wochen den gleichen Humbuck schreibst, wenns immer noch nicht ü 1,50 ist..

Aber naja, lange scheinst jedenfalls Dich noch nicht mit MDG und der Materie beschäftigt zu haben..  und nach fast 3000 Handelstagen und noch früherer Gründung, brauchts kein Durchsetzen in der BioSzene, sondern knallharte Forschungsfakten und Ergebnisse und vor allem CASH..

Sorry, aber ich les hier net mehr mit.. Voran bringen tut mich das hier absolut nicht..
Sorry  

94 Postings, 4669 Tage Aktien TraderMedigene 2012 viel versprechender

 
  
    #273
26.02.12 16:09

Lieber Leser,

es tut uns leid, dass Sie seit 7 Jahren hoffen und warten (Eigenes Risiko), aber wir würden Ihnen gerne empfehlen, dass Sie mit 3-4,00 € dies Jahr noch auszusteigen, ansonstens bereitet sich das Virus aus!

Zur Berühigung

http://www.medigene.de/de/home/

 

 

Viel Glück

 

94 Postings, 4669 Tage Aktien TraderPipeline & Marketresearch auf Englisch...

 
  
    #274
26.02.12 19:13

http://www.finanzen.net/nachricht/aktien/...ally-mit-Substanz-1665822

http://images.finanzen.net/mediacenter/unsortiert/...20_forschung.pdf

MDG kommt noch schneller als man denkt. Es gibt aktuell mehr als 4 Marketresearchs über MDGs Pipeline mit insgesamt 600 Mio € Umsatz.

 

Viel Glück

 

94 Postings, 4669 Tage Aktien TraderAntwort auf dieser Frage...

 
  
    #275
27.02.12 14:21

Ein Anstieg über 1,45 Euro wäre dann anschließend ein wichtiges Folge-Kaufsignal.

http://www.4investors.de/php_fe/index.php?sektion=stock&ID=55912

 

Viel Glück

 

Seite: < 1 | ... | 8 | 9 | 10 |
| 12 | 13 | 14 | ... 15  >  
   Antwort einfügen - nach oben